Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with water insoluble or poorly water soluble pharmaceutically active agents (PAA). The aggregates formed are specifically induced by interaction of PAA and homopolymer and are different from aggregates that are formed by the polymer alone in the absence of the PAA or by the PAA alone in the absence of the polymer. Such aggregates can be used to improve drug solubility, stability, delivery and efficacy.

Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with water insoluble or poorly water soluble pharmaceutically active agents (PAA). The aggregates formed are specifically induced by interaction of PAA and homopolymer and are different from aggregates that are formed by the polymer alone in the absence of the PAA or by the PAA alone in the absence of the polymer. Such aggregates can be used to improve drug solubility, stability, delivery and efficacy.

Abstract: Assays for detecting antibodies to pharmaceutical preparations, food allergens and environmental allergens are described.

Abstract: Compositions comprising an oxazoline polymer and optional linkers to carry a variety of molecules.

Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with water insoluble or poorly water soluble pharmaceutically active agents (PAA). The aggregates formed are specifically induced by interaction of PAA and homopolymer and are different from aggregates that are formed by the polymer alone in the absence of the PAA or by the PAA alone in the absence of the polymer. Such aggregates can be used to improve drug solubility, stability, delivery and efficacy.

Abstract: Compositions comprising an oxazoline polymer and optional linkers to carry a variety of molecules.

Abstract: Compositions comprising an oxazoline polymer and optional linkers to carry a variety of molecules.

Abstract: Compositions comprising an oxazoline polymer and optional linkers to carry a variety of molecules.

Abstract: Assays for detecting antibodies to pharmaceutical preparations, food allergens and environmental allergens are described.

Abstract: Modified branched polymers are combined with bioactive agents which are one member of a binding pair for use in an assay.

Abstract: Assays for detecting antibodies to pharmaceutical preparations, food allergens and environmental allergens are described.

Abstract: Modified branched polymers are combined with bioactive agents which are one member of a binding pair for use in an assay.

Abstract: Assays for detecting antibodies to pharmaceutical preparations, food allergens and environmental allergens are described.

Abstract: Compositions comprising an oxazoline polymer and optional linkers to carry a variety of molecules.

Abstract: Incorporation of modified branched polymers in one or more components of assays enhances sensitivity, specificity or both, providing powerful point of use tests.

Abstract: Modified symmetrically branched polymers are combined with bioactive agents for a variety of purposes including drug delivery and conjugation to one member of a binding pair for use in an assay.

Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with water insoluble or poorly water soluble pharmaceutically active agents (PAA). The aggregates formed are specifically induced by interaction of PAA and homopolymer and are different from aggregates that are formed by the polymer alone in the absence of the PAA or by the PAA alone in the absence of the polymer. Such aggregates can be used to improve drug solubility, stability, delivery and efficacy.

Abstract: Incorporation of modified branched polymers in one or more components of assays enhances sensitivity, specificity or both, providing powerful point of use tests.

Abstract: A conjugate of a modified randomly branched asymmetric polymer without a core and a member of a binding pair is described. The modified randomly branched asymmetric polymer can contain chain branches, terminal branches or both. The modified randomly branched asymmetric polymer can contain random asymmetric branches or random asymmetric junctions. The binding pair can be an antibody, antigen or a ligand.

Abstract: A conjugate of a modified randomly branched asymmetric polymer without a core and a member of a binding pair is described. The modified randomly branched asymmetric polymer can contain chain branches, terminal branches or both. The modified randomly branched asymmetric polymer can contain random asymmetric branches or random asymmetric junctions. The binding pair can be an antibody, antigen or a ligand. The conjugate includes a drug.